Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset. Issue 8 (3rd July 2021)

• Record Type: Journal Article
• Authors: Luan, Danny; Wu, Yiyuan; Goldstein, Jordan; Rutherford, Sarah; Leonard, John P.; Martin, Peter
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 8(2021)
• Page Start: 1850
• Page End: 1859
• Publication Date: 2021-07-03
• Subjects: Diffuse large B-cell lymphoma -- positron emission tomography-computed tomography -- bone marrow biopsy -- SEER-Medicare; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1889540
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Positron emission tomography-computed tomography (PET-CT) has become the primary modality for staging in diffuse large B-cell lymphoma (DLBCL), whereas the role of staging bone marrow biopsy (BMB) has become less clear. In this analysis, we included 7, 005 DLBCL patients in SEER-Medicare who received either PET-CT without BMB (PET-CT w/o BMB), CT with BMB (CT w/ BMB), or both PET-CT and BMB (PET-CT w/ BMB). The proportion of patients undergoing PET-CT increased across years of diagnosis, while the proportion undergoing CT or BMB decreased. In a fully adjusted Cox proportional hazards model, PET-CT w/ BMB was associated with a marginally superior OS compared to PET-CT w/o BMB. Notably, the association between PET-CT w/ BMB and OS was strongest in patients ≤70 years, but was not present when looking at individual stage of diagnosis. Overall, these data do not provide sufficient support to eliminate staging BMB in patients who undergo PET-CT.